The estimated Net Worth of Christine Berni Silverstein is at least $1.49 Миллион dollars as of 17 June 2024. Ms. Silverstein owns over 25,821 units of Abeona Therapeutics Inc stock worth over $346,932 and over the last 6 years she sold ABEO stock worth over $141,203. In addition, she makes $1,000,220 as Director at Abeona Therapeutics Inc.
Sign up
Ms. Silverstein ABEO stock SEC Form 4 insiders trading
Christine has made over 2 trades of the Abeona Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 25,821 units of ABEO stock worth $116,453 on 17 June 2024.
The largest trade she's ever made was selling 25,821 units of Abeona Therapeutics Inc stock on 17 June 2024 worth over $116,453. On average, Christine trades about 2,143 units every 18 days since 2019. As of 17 June 2024 she still owns at least 62,063 units of Abeona Therapeutics Inc stock.
You can see the complete history of Ms. Silverstein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christine Silverstein biography
Christine Berni Silverstein serves as Director of the Company. Ms. Silverstein became our Chief Financial Officer on January 7, 2019. Ms. Silverstein transitioned to Chief Financial Officer from Senior Vice President of Finance & Investor Relations, in January 2019 and brings 15 years of experience in capital markets strategy, financial services, investor relations and healthcare media communications to the Company. Prior to joining Abeona, she served as Head of Investor Relations at Relmada Therapeutics, Inc., a clinical stage, publicly-traded specialty pharmaceutical company. Before that, Ms. Silverstein was a Managing Director at SCO Financial Group, a New York-based corporate advisory firm, where she focused efforts on helping clients build robust investor relations infrastructures and providing strategic financial counsel. Earlier in her career, she held senior positions at two boutique New York investor and public relations agencies, The Investor Relations Group (IRG) and Corporate Profile LLC. Ms. Silverstein’s core focus during her agency tenure included consulting C-level management on capital markets strategies, media, fundraising initiatives, crisis management and regulatory issues. She began her career in the financial services as a registered investment advisor (RIA) at Royal Alliance Associates before moving to the investor and corporate relations industry. A member of the National Investor Relations Institute, Ms. Silverstein holds a B.S. from the Peter Tobin College of Business at St. John’s University. Senior Vice President, Investor Relations & Finance
What is the salary of Christine Silverstein?
As the Director of Abeona Therapeutics Inc, the total compensation of Christine Silverstein at Abeona Therapeutics Inc is $1,000,220. There are no executives at Abeona Therapeutics Inc getting paid more.
How old is Christine Silverstein?
Christine Silverstein is 37, she's been the Director of Abeona Therapeutics Inc since 2020. There are 7 older and no younger executives at Abeona Therapeutics Inc. The oldest executive at Abeona Therapeutics Inc is Jon Voss, 61, who is the VP & Head of Quality.
What's Christine Silverstein's mailing address?
Christine's mailing address filed with the SEC is 6555 CARNEGIE AVE, 4TH FLOOR, , CLEVELAND, OH, 44103.
Insiders trading at Abeona Therapeutics Inc
Over the last 15 years, insiders at Abeona Therapeutics Inc have traded over $4,486,735 worth of Abeona Therapeutics Inc stock and bought 427,809 units worth $1,765,143 . The most active insiders traders include Capital Partners Llc Rouhan..., Todd Wider и Michael Amoroso. On average, Abeona Therapeutics Inc executives and independent directors trade stock every 50 days with the average trade being worth of $256,542. The most recent stock trade was executed by Mark Alvino on 17 June 2024, trading 25,890 units of ABEO stock currently worth $116,764.
What does Abeona Therapeutics Inc do?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
What does Abeona Therapeutics Inc's logo look like?
Complete history of Ms. Silverstein stock trades at Abeona Therapeutics Inc и Marinus Pharmaceuticals Inc
Abeona Therapeutics Inc executives and stock owners
Abeona Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Christine Silverstein,
Director -
Dr. Brendan M. O'Malley J.D., Ph.D.,
Sr. VP & Gen. Counsel -
Dr. Vishwas Seshadri M.B.A., Ph.D.,
Pres, CEO & Director -
Edward G. Carr,
Sr. VP, CFO & Chief Accounting Officer -
Todd Wider,
Independent Director -
Paul Mann,
Independent Director -
Michael Amoroso,
Chief Operating Officer -
Edward Carr,
Principal Financial Officer, Chief Accounting Officer, Vice President -
Alison Hardgrove,
VP of HR -
Joseph Walter Vazzano,
CFO, Principal Financial Officer & Principal Accounting Officer -
Sofia Warner,
Sr. Director of Investor Relations -
Jon Voss,
VP & Head of Quality -
Scott Nogi M.B.A.,
VP & Head of Bus. Operation -
Kristina Maximenko,
VP of HR -
Scott Santiamo,
Director of Corp. Communications -
Gregory Gin,
VP of Investor Relations & Corp. Communications -
Brian Kevany Ph.D.,
VP & Chief Technical Officer -
Mark Alvino,
Director -
Mark J Ahn,
Director -
Carsten Thiel,
Chief Executive Officer -
Timothy J Miller,
See Remarks -
George V Migausky,
Director -
B Davis Jeffrey,
Chief Operating Officer -
Stephen B Thompson,
VP-Finance Chief Acctg Officer -
Capital Management, L.P.Atc...,
-
Joao Md Siffert,
Chief Executive Officer -
Stephen B. Howell,
Director -
Steven H Rouhandeh,
Director -
Shawn Tomasello,
Director -
Stefano Buono,
Director -
Duyne Richard B Van,
Director -
Brian Jg Pereira,
Executive Chairman -
Capital Partners Llc Rouhan...,
-
Leila Alland,
Director -
Faith L. Charles,
Director -
Donald A. Wuchterl,
Director -
Brendan M. O'malley,
SVP, General Counsel -
Joseph Walter Vazzano,
Chief Financial Officer -
Bernhardt G Zeiher,
Director -
Eric Crombez,
Director